恒宇信通 reported revenue of ¥0.05B for the period ended 2026-06-30, -42.3% year on year. Net income was ¥-0.02B, a -32.7% net margin on a 47.7% gross margin. The largest revenue line is 航空产品销售收入 at 83% of the total. Free cash flow for the period was ¥-0.03B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.05B | -42.3% |
| Gross profit | ¥0.02B | — |
| Operating income | ¥-0.02B | — |
| Net income | ¥-0.02B | -189.4% |
| Gross margin | 47.7% | Net margin -32.7% |
| Revenue Q/Q | -12.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| 航空产品销售收入 | ¥0.04B | 82.7% |
| 技术服务收入 | ¥0.01B | 14.9% |
| 其他(补充) | ¥0.00B | 2.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.03B | 52.3% |
| R&D | ¥0.01B | 24.2% |
| SG&A | ¥0.02B | 34.1% |
| Tax & other | ¥-0.00B | -0.2% |
| Item | Amount |
|---|---|
| Total assets | ¥1.43B |
| Total liabilities | ¥0.23B |
| Shareholders' equity | ¥1.20B |
| Equity / assets | 84.0% |
| Operating cash flow | ¥-0.03B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥-0.03B |
| Cash conversion (OCF / net income) | 363% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
共同药业 ・ 晓鸣股份 ・ 格林精密 ・ 恒帅股份 ・ 华绿生物 ・ 博亚精工 ・ 万辰集团 ・ 立高食品 ・ 商络电子 ・ 达瑞电子 ・ 深圳瑞捷 ・ 东箭科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies